Lupus Highlights

• Abstract 1316:  Novel Combined response endpoint and systemic lupus erythematosus (SLE) Flare Index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy.
• Abstract 1318:  Peptide mimotope of DNA blocks toll like receptor (TLR) 9 activation.
• Abstract 1315:  MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus.
• Abstract 1317:  A randomized placebo-controlled trial of omega-3-polyunsaturated fatty acids on disease activity and endothelial function in systemic lupus erythematosus.
• Abstract 1320:  Efficacy of fulvestrant-an estrogen receptor blocker-in Human SLE:  A one-year double-blind placebo-controlled trial; clinical, serological, bone density, and molecular studies.
• Abstract 2057:  Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins.
• Abstract 2056: IFN-regulated chemokines are reliable biomarkers of systemic lupus erythematosus disease activity.
• Abstract L13: Mycophenolate Mofetil and Intravenous Cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by Racial Group